A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Organon & Co. OGN
Mixed broader-coverage candidate · Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies.
On FrontierLab's discovery record since 2026-08-10 (11 days ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-11), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | -2.5% |
|---|---|
| Gross margin | 53% |
| Gross profits / assets | 0.25 |
| Rule of 40 | 16.8 |
| Net margin | 19.3% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 0.6 |
Quality checklist
- ✗ Revenue growth — -2.5% (pass ≥ 20%)
- ~ Gross profits / assets — 0.25 (pass ≥ 0.33)
- ~ Gross margin — 53% (pass ≥ 60%)
- ✓ Cash generation
- ~ Share dilution — 4%
Fundamentals — snapshot as of 2026-08-11
| Stage | Established |
|---|---|
| Share issuance (YoY) | 4% · modest issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | 17.7 |
| EPS (trailing) | $0.77 |
| Burn multiple | — |
| Gross-margin trend (pts) | -3.3 |
| Cash / assets | 0.09 |
| Net debt / EBITDA | 5.7 |
| Statements as of | Q2 FY2026 · filed 2026-07-31 |
Momentum context — a snapshot from 2026-08-11, not current
| Price at surface | $13.62 (as of 2026-08-11) |
|---|---|
| 52-week range | $5.69 – $13.63 |
| % off 52-wk high | -0.1% |
| RSI (14) | 69 |
| Relative volume | 0.5× |
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-11 (end-of-day). How grades are computed →